The law firm of Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating potential federal securities claims against Amarin Corporation plc (“Amarin” or the “Company”) and certain of its officers and directors in connection with allegations that the Company made materially false and misleading statements regarding prospective FDA approval of the proposed “ANCHOR” indication for the Company’s Vascepa drug.
On October 16, 2013, the NASD halted trading in Amarin common stock while the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee considered results of the ANCHOR study, which questioned the drug’s efficacy in treating severe cardiovascular events, and voted 9-2 to reject the New Drug Application for the ANCHOR indication of Vascepa.
On this news, and upon resumption of trading on October 17, 2013, Amarin common stock declined over 60% from $5.17 per share to $2.01 per share on heavy trading volume.
Wolf Haldenstein has represented individual and institutional investors for many years, serving as lead counsel in numerous cases in United States federal and state courts. Please visit the Wolf Haldenstein website (
) for more information about the firm.
Please contact us
no later than January 3, 2014
if you own Amarin securities and wish to discuss this matter with us, or have any questions concerning your rights and interests:
Gregory M. Nespole, Esq.Wolf Haldenstein Adler Freeman & Herz LLP270 Madison AvenueNew York, New York 10016
Phone Numbers:(800) 575-0735(212) 545-4657(917) 515-6161
and please reference “Amarin Investigation.”